Anagrelide and Mutational Status in Essential Thrombocythemia

Area of Science:

• Hematology
• Oncology
• Pharmacogenomics

Background:

• Anagrelide is a platelet-lowering agent used for essential thrombocythemia (ET).
• Its efficacy is established, but the impact of specific gene mutations (JAK2, CALR, MPL) on treatment response is not fully understood.
• Understanding these mutations is crucial for personalized ET management.

Purpose of the Study:

• To investigate the influence of Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus (MPL) gene mutations on anagrelide treatment response in ET patients.
• To evaluate anagrelide's effectiveness in ET patients with different mutational profiles.

Main Methods:

• Retrospective analysis of 21 ET patients treated with anagrelide as second-line therapy.
• Assessment of JAK2, CALR, and MPL mutational status from DNA samples.
• Evaluation of platelet response after a median follow-up of 4.6 years.

Main Results:

• Of 21 patients, 7 had JAK2 mutations, 7 had CALR mutations, and 7 were triple-negative.
• Anagrelide achieved a partial platelet response in 76.2% of patients.
• Patients with JAK2 mutations or triple-negative status showed comparable responses, while all 5 non-responders had CALR mutations.

Conclusions:

• Anagrelide therapy appears less effective in ET patients with CALR mutations.
• Mutational status, particularly CALR, may be a key factor in predicting anagrelide response in ET.
• Personalized therapeutic strategies considering genetic profiles are recommended for ET management.